New trial available: Click on any alert below and access our regulatory alerts and get timely notifications sent to your inbox for 7 days.
1st December 2022
US - Nevada: The Nevada Cannabis Compliance Board (CCB) has issued 20 prospective licences for cannabis consumption lounges that were determined via a lottery of applicants. Ten provisional licences were issued to social equity applicants (applicants who have been convicted of a cannabis offence, had a family member convicted of a cannabis offence, or who lived in an area impacted by a prohibitionist drug policy). Prospective licensees must still pass a suitability investigation by the CCB before their licences will be issued. Another 20 applicants were approved for consumption lounges that must be attached to a licensed operational cannabis dispensary.
17th October 2022
US - Nevada: The Nevada Cannabis Compliance Board (CCB) is now accepting applications for cannabis consumption lounges. The application process is open until 27th October.
15th September 2022
US - Nevada: A judge has ruled that the Nevada Board of Pharmacy may no longer list cannabis as a Schedule I drug, press reports. The American Civil Liberties Union (ACLU), which brought the lawsuit, claimed the Schedule I listing, despite voters passing an initiative in 2016 to legalise cannabis, created a loophole that allowed law enforcement to arrest people unjustly for cannabis offences.
22nd August 2022
29th June 2022
US - Nevada: The Nevada Cannabis Compliance Board (CCB) has unanimously approved regulations for cannabis lounges. The regulations allow for the sale of single-use cannabis products in limited amounts and for the sale of hemp and CBD products in the lounges. “The CCB expects to open the first licensing round for consumption lounges in the Fall, allowing for the first consumption lounges to open as early as the end of the year,” the board said.
2nd March 2022
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.